Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.
Ascierto ML, Makohon-Moore A, Lipson EJ, Taube JM, McMiller TL, Berger AE, Fan J, Kaunitz GJ, Cottrell TR, Kohutek ZA, Favorov A, Makarov V, Riaz N, Chan TA, Cope L, Hruban RH, Pardoll DM, Taylor BS, Solit DB, Iacobuzio-Donahue CA, Topalian SL. Ascierto ML, et al. Among authors: cottrell tr. Clin Cancer Res. 2017 Jun 15;23(12):3168-3180. doi: 10.1158/1078-0432.CCR-17-0270. Epub 2017 Feb 13. Clin Cancer Res. 2017. PMID: 28193624 Free PMC article.
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H, Esandrio J, Anders RA, Cope L, Pardoll DM, Drake CG, Taube JM. Danilova L, et al. Among authors: cottrell tr. Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777. doi: 10.1073/pnas.1607836113. Epub 2016 Nov 11. Proc Natl Acad Sci U S A. 2016. PMID: 27837027 Free PMC article.
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
Sunshine JC, Nguyen PL, Kaunitz GJ, Cottrell TR, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KB, Cornish TC, Lipson EJ, Anders RA, Taube JM. Sunshine JC, et al. Among authors: cottrell tr. Clin Cancer Res. 2017 Aug 15;23(16):4938-4944. doi: 10.1158/1078-0432.CCR-16-1821. Epub 2017 Apr 20. Clin Cancer Res. 2017. PMID: 28428193 Free PMC article.
Melanoma subtypes demonstrate distinct PD-L1 expression profiles.
Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH, Kraft S, Gerstenblith MR, Thompson CL, Honda K, Cuda JD, Eberhart CG, Handa JT, Lipson EJ, Taube JM. Kaunitz GJ, et al. Among authors: cottrell tr. Lab Invest. 2017 Sep;97(9):1063-1071. doi: 10.1038/labinvest.2017.64. Epub 2017 Jul 24. Lab Invest. 2017. PMID: 28737763 Free PMC article.
Implications of the tumor immune microenvironment for staging and therapeutics.
Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A. Taube JM, et al. Among authors: cottrell tr. Mod Pathol. 2018 Feb;31(2):214-234. doi: 10.1038/modpathol.2017.156. Epub 2017 Dec 1. Mod Pathol. 2018. PMID: 29192647 Free PMC article. Review.
PD-L1 expression in inflammatory myofibroblastic tumors.
Cottrell TR, Duong AT, Gocke CD, Xu H, Ogurtsova A, Taube JM, Belchis DA. Cottrell TR, et al. Mod Pathol. 2018 Jul;31(7):1155-1163. doi: 10.1038/s41379-018-0034-6. Epub 2018 Feb 15. Mod Pathol. 2018. PMID: 29449680 Free PMC article.
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Forde PM, et al. Among authors: cottrell tr. N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. N Engl J Med. 2018. PMID: 29658848 Free PMC article. Clinical Trial.
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM. Cottrell TR, et al. Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218. Ann Oncol. 2018. PMID: 29982279 Free PMC article. Clinical Trial.
39 results